anti mouse c4  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech anti mouse c4
    Anti Mouse C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti mouse c4 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    anti mouse c4  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech anti mouse c4
    Anti Mouse C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti mouse c4 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    anti mouse c4  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech anti mouse c4
    Complement component <t>C4</t> and C5 expression in WT and Mdr2-KO mouse livers. (A) Liver sections were stained with Clec4f (green) for KCs, C4 (red), and DAPI for nuclei (blue). Dotted lines demarcate Clecf + cells as well as immune cell infiltrates in portal triads from adjacent liver parenchyma. (B) Liver sections were stained with Clec4f (green) for KCs, C5 (red), and DAPI (blue) for nuclei. (C) Complement component C3, C1q, CD68 expression in WT and Mdr2-KO livers. Liver sections were stained with C3 (red), C1q (white), and CD68 (green) for macrophages/KCs and DAPI for nuclei (blue). Dotted lines demarcate immune cell infiltration sites from adjacent liver parenchyma. White squares represent high magnification images shown separately. Representative images of WT livers (n=6); Mdr2-KO livers (n=6) are shown. Scale bars 100 μm in images of low and high magnification.
    Anti Mouse C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti mouse c4 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    1) Product Images from "The C1q-ApoE complex: A new hallmark pathology of viral hepatitis and nonalcoholic fatty liver disease"

    Article Title: The C1q-ApoE complex: A new hallmark pathology of viral hepatitis and nonalcoholic fatty liver disease

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2022.970938

    Complement component C4 and C5 expression in WT and Mdr2-KO mouse livers. (A) Liver sections were stained with Clec4f (green) for KCs, C4 (red), and DAPI for nuclei (blue). Dotted lines demarcate Clecf + cells as well as immune cell infiltrates in portal triads from adjacent liver parenchyma. (B) Liver sections were stained with Clec4f (green) for KCs, C5 (red), and DAPI (blue) for nuclei. (C) Complement component C3, C1q, CD68 expression in WT and Mdr2-KO livers. Liver sections were stained with C3 (red), C1q (white), and CD68 (green) for macrophages/KCs and DAPI for nuclei (blue). Dotted lines demarcate immune cell infiltration sites from adjacent liver parenchyma. White squares represent high magnification images shown separately. Representative images of WT livers (n=6); Mdr2-KO livers (n=6) are shown. Scale bars 100 μm in images of low and high magnification.
    Figure Legend Snippet: Complement component C4 and C5 expression in WT and Mdr2-KO mouse livers. (A) Liver sections were stained with Clec4f (green) for KCs, C4 (red), and DAPI for nuclei (blue). Dotted lines demarcate Clecf + cells as well as immune cell infiltrates in portal triads from adjacent liver parenchyma. (B) Liver sections were stained with Clec4f (green) for KCs, C5 (red), and DAPI (blue) for nuclei. (C) Complement component C3, C1q, CD68 expression in WT and Mdr2-KO livers. Liver sections were stained with C3 (red), C1q (white), and CD68 (green) for macrophages/KCs and DAPI for nuclei (blue). Dotted lines demarcate immune cell infiltration sites from adjacent liver parenchyma. White squares represent high magnification images shown separately. Representative images of WT livers (n=6); Mdr2-KO livers (n=6) are shown. Scale bars 100 μm in images of low and high magnification.

    Techniques Used: Expressing, Staining

    c4, mouse, mab 16d2  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech c4, mouse, mab 16d2
    C4, Mouse, Mab 16d2, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c4, mouse, mab 16d2/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    c4, mouse, mab 16d2 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    rat anti c4b  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech rat anti c4b
    (A) UMAP visualization and annotation of 5 sub-clusters within the oligodendrocyte lineage across all samples; 2,300 cells at 3mo and 1,480 cells at 7mo. (B) Stacked bar graph displaying cell percentage of each cluster identifies the appearance of reactive oligodendrocytes (red bar) in 7mo APP23xPS45 and APP23xPS45xIPD mice. (C) Volcano plot showing DEGs between APP23xPS45 versus WT mice in the oligodendrocyte cluster at 7mo. (D) Violin plot showing the expression of <t>C4b,</t> Serpina3n and B2m within reactive oligodendrocytes (Cl.5) across all genotypes at 7mo. (E) Representative images of RNAscope-ISH for Serpina3n and Sox10 probes (upper panel) and immunofluorescence for C4b and Olig2 co-staining (lower panel) in the cortex of APP23xPS45 and APP23xPS45xIPD mice at 7mo. (F) Quantification of percentage and expression (denoted by puncta/cell) of Serpina3n and C4b in oligodendrocytes based on RNAscope-ISH and immunofluorescence images; n represents number of images from 3 independent mice. (G) Same as D, expression in 3mo mice. Error bars represent SEM. Unpaired t-test; p=0.8327, p=0.5367, p=0.3246, p=0.2215. Scale bar= 20μm upper panel, 50μm lower panel.
    Rat Anti C4b, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti c4b/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti c4b - by Bioz Stars, 2024-04
    92/100 stars

    Images

    1) Product Images from "Sustained TREM2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer’s disease"

    Article Title: Sustained TREM2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer’s disease

    Journal: bioRxiv

    doi: 10.1101/2021.06.23.449405

    (A) UMAP visualization and annotation of 5 sub-clusters within the oligodendrocyte lineage across all samples; 2,300 cells at 3mo and 1,480 cells at 7mo. (B) Stacked bar graph displaying cell percentage of each cluster identifies the appearance of reactive oligodendrocytes (red bar) in 7mo APP23xPS45 and APP23xPS45xIPD mice. (C) Volcano plot showing DEGs between APP23xPS45 versus WT mice in the oligodendrocyte cluster at 7mo. (D) Violin plot showing the expression of C4b, Serpina3n and B2m within reactive oligodendrocytes (Cl.5) across all genotypes at 7mo. (E) Representative images of RNAscope-ISH for Serpina3n and Sox10 probes (upper panel) and immunofluorescence for C4b and Olig2 co-staining (lower panel) in the cortex of APP23xPS45 and APP23xPS45xIPD mice at 7mo. (F) Quantification of percentage and expression (denoted by puncta/cell) of Serpina3n and C4b in oligodendrocytes based on RNAscope-ISH and immunofluorescence images; n represents number of images from 3 independent mice. (G) Same as D, expression in 3mo mice. Error bars represent SEM. Unpaired t-test; p=0.8327, p=0.5367, p=0.3246, p=0.2215. Scale bar= 20μm upper panel, 50μm lower panel.
    Figure Legend Snippet: (A) UMAP visualization and annotation of 5 sub-clusters within the oligodendrocyte lineage across all samples; 2,300 cells at 3mo and 1,480 cells at 7mo. (B) Stacked bar graph displaying cell percentage of each cluster identifies the appearance of reactive oligodendrocytes (red bar) in 7mo APP23xPS45 and APP23xPS45xIPD mice. (C) Volcano plot showing DEGs between APP23xPS45 versus WT mice in the oligodendrocyte cluster at 7mo. (D) Violin plot showing the expression of C4b, Serpina3n and B2m within reactive oligodendrocytes (Cl.5) across all genotypes at 7mo. (E) Representative images of RNAscope-ISH for Serpina3n and Sox10 probes (upper panel) and immunofluorescence for C4b and Olig2 co-staining (lower panel) in the cortex of APP23xPS45 and APP23xPS45xIPD mice at 7mo. (F) Quantification of percentage and expression (denoted by puncta/cell) of Serpina3n and C4b in oligodendrocytes based on RNAscope-ISH and immunofluorescence images; n represents number of images from 3 independent mice. (G) Same as D, expression in 3mo mice. Error bars represent SEM. Unpaired t-test; p=0.8327, p=0.5367, p=0.3246, p=0.2215. Scale bar= 20μm upper panel, 50μm lower panel.

    Techniques Used: Expressing, Immunofluorescence, Staining

    anti mouse c4  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech anti mouse c4
    ( a ) ChPs were stained for complement C3 (red), anaphylatoxin C3a (cyan), and Ig (green). Bar 100 μm. ( b ) Complement C5. ChPs were stained for complement C5 (red). Bar 10 μm. ( c ) Liver-targeted C5-siRNA reduces serum C5. Control (n = 9 mice), C5 (n=9). ( d-f ) C5-siRNA attenuates leukocyte infiltration ( d ), CD68 + macrophage/DC infiltration ( e ), and CD3 + T cell infiltration ( f ) in ApoE -/- ChPs. Bars 10 μm. Control (n = 6 mice), C5 (6). ( g ) Low <t>C4</t> and C3 protein levels in lipid deposits of HFD ApoE4 ChPs. Serial sections of ChPs as shown in were stained for C4 (green) and C3 (red). ( h ) Super-resolution (STED) microscopy shows colocalization of C1q (green) and ApoE (red) in HFD ApoE4 ChPs. Bar 10 μm. ( i ) ChP complement mRNA expression. WT (n=4 mice); ApoE -/- (n=5); ND ApoE3 (n=6); HFD ApoE3 (n=6); ND ApoE4 (n=6); HFD ApoE4 (n=6). Data in a,b,g,h are representative images from at least 3 independent mouse samples. Data represent means± SEM; Two-tailed Student´s t-test was applied to c,d,e,f. *** P <0.0001; one-way ANOVA with Tukey’s test was applied to i. Gene names in .
    Anti Mouse C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti mouse c4 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    1) Product Images from "ApoE attenuates unresolvable inflammation by complex formation with activated C1q"

    Article Title: ApoE attenuates unresolvable inflammation by complex formation with activated C1q

    Journal: Nature medicine

    doi: 10.1038/s41591-018-0336-8

    ( a ) ChPs were stained for complement C3 (red), anaphylatoxin C3a (cyan), and Ig (green). Bar 100 μm. ( b ) Complement C5. ChPs were stained for complement C5 (red). Bar 10 μm. ( c ) Liver-targeted C5-siRNA reduces serum C5. Control (n = 9 mice), C5 (n=9). ( d-f ) C5-siRNA attenuates leukocyte infiltration ( d ), CD68 + macrophage/DC infiltration ( e ), and CD3 + T cell infiltration ( f ) in ApoE -/- ChPs. Bars 10 μm. Control (n = 6 mice), C5 (6). ( g ) Low C4 and C3 protein levels in lipid deposits of HFD ApoE4 ChPs. Serial sections of ChPs as shown in were stained for C4 (green) and C3 (red). ( h ) Super-resolution (STED) microscopy shows colocalization of C1q (green) and ApoE (red) in HFD ApoE4 ChPs. Bar 10 μm. ( i ) ChP complement mRNA expression. WT (n=4 mice); ApoE -/- (n=5); ND ApoE3 (n=6); HFD ApoE3 (n=6); ND ApoE4 (n=6); HFD ApoE4 (n=6). Data in a,b,g,h are representative images from at least 3 independent mouse samples. Data represent means± SEM; Two-tailed Student´s t-test was applied to c,d,e,f. *** P <0.0001; one-way ANOVA with Tukey’s test was applied to i. Gene names in .
    Figure Legend Snippet: ( a ) ChPs were stained for complement C3 (red), anaphylatoxin C3a (cyan), and Ig (green). Bar 100 μm. ( b ) Complement C5. ChPs were stained for complement C5 (red). Bar 10 μm. ( c ) Liver-targeted C5-siRNA reduces serum C5. Control (n = 9 mice), C5 (n=9). ( d-f ) C5-siRNA attenuates leukocyte infiltration ( d ), CD68 + macrophage/DC infiltration ( e ), and CD3 + T cell infiltration ( f ) in ApoE -/- ChPs. Bars 10 μm. Control (n = 6 mice), C5 (6). ( g ) Low C4 and C3 protein levels in lipid deposits of HFD ApoE4 ChPs. Serial sections of ChPs as shown in were stained for C4 (green) and C3 (red). ( h ) Super-resolution (STED) microscopy shows colocalization of C1q (green) and ApoE (red) in HFD ApoE4 ChPs. Bar 10 μm. ( i ) ChP complement mRNA expression. WT (n=4 mice); ApoE -/- (n=5); ND ApoE3 (n=6); HFD ApoE3 (n=6); ND ApoE4 (n=6); HFD ApoE4 (n=6). Data in a,b,g,h are representative images from at least 3 independent mouse samples. Data represent means± SEM; Two-tailed Student´s t-test was applied to c,d,e,f. *** P <0.0001; one-way ANOVA with Tukey’s test was applied to i. Gene names in .

    Techniques Used: Staining, Microscopy, Expressing, Two Tailed Test

    ( a ) ChPs were stained for C1q (red) and C4 (green). Bar 100 µm. ( b ) C5 siRNA treatment blocks C5 protein deposition in ApoE-/- ChPs; ( c ) ChPs were stained for C3. Ig represents lipid; ( d ) Serum C3 and C5. Serum C3 and C5 protein levels were measured by ELISA. ApoE-/-(n = 6 mice), HFD ApoE4 (n=5). ( e ) High resolution confocal microscopy shows colocalization of ApoE4 (ApoE, red) and Ig (green, represents lipid) in HFD ApoE4-KI ChPs. ApoE-/- ChPs serve as negative controls for ApoE staining; ( f) Complement regulators are expressed in ChPs. WT (n = 5 mice); ApoE-/-(n=4); ND ApoE3 (n=6); HFD ApoE3 (n=6); ND ApoE4 (n=6); HFD ApoE4 (n=6). ( g ) ChP Factor H expressed between WT and ApoE-/- mice. WT (n=5); ApoE-/-(n=4); (h) ChP factor H protein in ChPs. White arrows indicate lipid positive areas. Data in a,b,c,e,h are representative images from at least 3 biologically independent mouse samples. Data in d,f,g represent means ± SEM; Two-tailed Student's t-test was applied to d,g; one-way ANOVA with Tukey posttest was applied to f; Gene names in .
    Figure Legend Snippet: ( a ) ChPs were stained for C1q (red) and C4 (green). Bar 100 µm. ( b ) C5 siRNA treatment blocks C5 protein deposition in ApoE-/- ChPs; ( c ) ChPs were stained for C3. Ig represents lipid; ( d ) Serum C3 and C5. Serum C3 and C5 protein levels were measured by ELISA. ApoE-/-(n = 6 mice), HFD ApoE4 (n=5). ( e ) High resolution confocal microscopy shows colocalization of ApoE4 (ApoE, red) and Ig (green, represents lipid) in HFD ApoE4-KI ChPs. ApoE-/- ChPs serve as negative controls for ApoE staining; ( f) Complement regulators are expressed in ChPs. WT (n = 5 mice); ApoE-/-(n=4); ND ApoE3 (n=6); HFD ApoE3 (n=6); ND ApoE4 (n=6); HFD ApoE4 (n=6). ( g ) ChP Factor H expressed between WT and ApoE-/- mice. WT (n=5); ApoE-/-(n=4); (h) ChP factor H protein in ChPs. White arrows indicate lipid positive areas. Data in a,b,c,e,h are representative images from at least 3 biologically independent mouse samples. Data in d,f,g represent means ± SEM; Two-tailed Student's t-test was applied to d,g; one-way ANOVA with Tukey posttest was applied to f; Gene names in .

    Techniques Used: Staining, Enzyme-linked Immunosorbent Assay, Confocal Microscopy, Two Tailed Test

    ( a ) C1q binds immobilized malondialdehyde-modified LDL (MDA-LDL) and oxLDL but not native LDL or gelatin. ( b ) ApoE isoforms in NHS were added to MDA-LDL-coated microtiter plates and C4b deposition was determined by specific antisera. ( c , d ) IgM, MDA-LDL, and Aβ fibrils but not soluble Aβ activate complement and cause C3b deposition. BSA, gelatin as negative controls; ( e , f ) ApoE3 was incubated with either ( e ) C2 or ( f ) C4 in the presence of C1s. C2 and C4 were cleaved to their active forms C2a (α′30) and C4b (α′83) via C1s as revealed by the cleavage products in Western blot analyses; ( g ) ApoE3 has no cofactor activity for factor I in the cleavage of C4b to inactive iC4b. ApoE3 was incubated together with factor I, C4BP and C4b, and cleavage products were detected by Western blot analysis as indicated (α′25 and α′13). Full scanned blot images in e,f,g are available from source data figures. Data in a-d represent means ± SEM of three independent experiments. Two-tailed Student's t-test. Data in e,f,g are representative from 3 independent experiments.
    Figure Legend Snippet: ( a ) C1q binds immobilized malondialdehyde-modified LDL (MDA-LDL) and oxLDL but not native LDL or gelatin. ( b ) ApoE isoforms in NHS were added to MDA-LDL-coated microtiter plates and C4b deposition was determined by specific antisera. ( c , d ) IgM, MDA-LDL, and Aβ fibrils but not soluble Aβ activate complement and cause C3b deposition. BSA, gelatin as negative controls; ( e , f ) ApoE3 was incubated with either ( e ) C2 or ( f ) C4 in the presence of C1s. C2 and C4 were cleaved to their active forms C2a (α′30) and C4b (α′83) via C1s as revealed by the cleavage products in Western blot analyses; ( g ) ApoE3 has no cofactor activity for factor I in the cleavage of C4b to inactive iC4b. ApoE3 was incubated together with factor I, C4BP and C4b, and cleavage products were detected by Western blot analysis as indicated (α′25 and α′13). Full scanned blot images in e,f,g are available from source data figures. Data in a-d represent means ± SEM of three independent experiments. Two-tailed Student's t-test. Data in e,f,g are representative from 3 independent experiments.

    Techniques Used: Modification, Incubation, Western Blot, Activity Assay, Two Tailed Test

    ( a ) ApoE isoforms bind to the C1 complex, but not to C4 or C2. Biotinylated ApoE was immobilized on streptavidin-coated sensors and incubated with C1 complex, C4, C2, or buffer; ( b ) The C1 complex binds to immobilized ApoE isoforms. ( c ) ApoE isoforms bind to C1 and factor H, but not to C3 or C3b; ( d ) Normal human serum (NHS)-derived C1 binds to immobilized plasma-purified ApoE3 and to recombinant ApoE isoforms; ( e ) C1q binds to immobilized plasma-purified ApoE3 and to all recombinant ApoE isoforms; ( f ) Plasma-purified C1q was coated on a sensor chip (CM5) and plasma-derived ApoE (62-1000 nM) was injected into the fluid phase (75 mM NaCl, 5 mM HEPES, 1 mM CaCl2). ( g ) Mannose-binding lectin (MBL) does not bind to C1q as determined by biolayer interferometry; ( h ) Apolipoprotein A (ApoA) does not bind to C1q as determined by biolayer interferometry. ( i ) C1q-ApoE complexes revealed by proximity ligation assay (PLA) on cultured human apoptotic cells (THP-1) were detectable when treated with NHS but not with C1q-depleted serum (dNHS). Data represent mean fluorescence intensity (MFI) ± SEM of 16 cells for each group. Bar 10 µm. Data in b,c,d,e represent means ± SEM of at least three independent experiments. Data a,f,g and h represent means of at least two independent experiments. Two-tailed Student's t-test.
    Figure Legend Snippet: ( a ) ApoE isoforms bind to the C1 complex, but not to C4 or C2. Biotinylated ApoE was immobilized on streptavidin-coated sensors and incubated with C1 complex, C4, C2, or buffer; ( b ) The C1 complex binds to immobilized ApoE isoforms. ( c ) ApoE isoforms bind to C1 and factor H, but not to C3 or C3b; ( d ) Normal human serum (NHS)-derived C1 binds to immobilized plasma-purified ApoE3 and to recombinant ApoE isoforms; ( e ) C1q binds to immobilized plasma-purified ApoE3 and to all recombinant ApoE isoforms; ( f ) Plasma-purified C1q was coated on a sensor chip (CM5) and plasma-derived ApoE (62-1000 nM) was injected into the fluid phase (75 mM NaCl, 5 mM HEPES, 1 mM CaCl2). ( g ) Mannose-binding lectin (MBL) does not bind to C1q as determined by biolayer interferometry; ( h ) Apolipoprotein A (ApoA) does not bind to C1q as determined by biolayer interferometry. ( i ) C1q-ApoE complexes revealed by proximity ligation assay (PLA) on cultured human apoptotic cells (THP-1) were detectable when treated with NHS but not with C1q-depleted serum (dNHS). Data represent mean fluorescence intensity (MFI) ± SEM of 16 cells for each group. Bar 10 µm. Data in b,c,d,e represent means ± SEM of at least three independent experiments. Data a,f,g and h represent means of at least two independent experiments. Two-tailed Student's t-test.

    Techniques Used: Incubation, Derivative Assay, Purification, Recombinant, Injection, Binding Assay, Proximity Ligation Assay, Cell Culture, Fluorescence, Two Tailed Test

    complement c4  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech complement c4
    Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and <t>C4</t> (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.
    Complement C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complement c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    complement c4 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    1) Product Images from "Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression"

    Article Title: Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression

    Journal: Cancer research

    doi: 10.1158/0008-5472.CAN-17-0240

    Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.
    Figure Legend Snippet: Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.

    Techniques Used: Injection, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Confocal Microscopy, Ex Vivo, Luciferase, Tumor Implantation

    Age and gender-matched WT and C3−/− mice were injected with LLC-luc tumors, and primary tumors, organs, and whole blood were collected at the terminal sacrifice 21 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or LLC-luc tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+LLC-luc n = 21; naïve C3−/− n = 4; C3−/−+LLC-luc n = 4). Same data from naïve WT and C3−/− mice are used in this graph. (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in tumor specimens induced by LLC-luc from C3−/− were evaluated by confocal microscopy. (C) Primary tumor volumes 21 days after LLC-luc implantation in WT or C3−/− mice are shown (WT n = 18; C3−/− n = 11). (D and E) Number of metastases to the secondary pulmonary space and liver were counted from ex vivo images that captured the luciferase activities of LLC-luc metastases (Pulmonary metastasis - WT n = 18; C3−/− n = 11 and Liver metastasis - WT n = 14; C3−/− n = 9). (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 21 days after tumor implantation in both treated groups and vehicle or control peptide group are shown (F, n = 5 and G, n = 5 each group). *p <0.05. Error bars represent mean ± SEM.
    Figure Legend Snippet: Age and gender-matched WT and C3−/− mice were injected with LLC-luc tumors, and primary tumors, organs, and whole blood were collected at the terminal sacrifice 21 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or LLC-luc tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+LLC-luc n = 21; naïve C3−/− n = 4; C3−/−+LLC-luc n = 4). Same data from naïve WT and C3−/− mice are used in this graph. (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in tumor specimens induced by LLC-luc from C3−/− were evaluated by confocal microscopy. (C) Primary tumor volumes 21 days after LLC-luc implantation in WT or C3−/− mice are shown (WT n = 18; C3−/− n = 11). (D and E) Number of metastases to the secondary pulmonary space and liver were counted from ex vivo images that captured the luciferase activities of LLC-luc metastases (Pulmonary metastasis - WT n = 18; C3−/− n = 11 and Liver metastasis - WT n = 14; C3−/− n = 9). (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 21 days after tumor implantation in both treated groups and vehicle or control peptide group are shown (F, n = 5 and G, n = 5 each group). *p <0.05. Error bars represent mean ± SEM.

    Techniques Used: Injection, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Confocal Microscopy, Ex Vivo, Luciferase, Tumor Implantation

    complement c4  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech complement c4
    Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and <t>C4</t> (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.
    Complement C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complement c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    complement c4 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    1) Product Images from "Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression"

    Article Title: Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression

    Journal: Cancer research

    doi: 10.1158/0008-5472.CAN-17-0240

    Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.
    Figure Legend Snippet: Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.

    Techniques Used: Injection, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Confocal Microscopy, Ex Vivo, Luciferase, Tumor Implantation

    Age and gender-matched WT and C3−/− mice were injected with LLC-luc tumors, and primary tumors, organs, and whole blood were collected at the terminal sacrifice 21 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or LLC-luc tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+LLC-luc n = 21; naïve C3−/− n = 4; C3−/−+LLC-luc n = 4). Same data from naïve WT and C3−/− mice are used in this graph. (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in tumor specimens induced by LLC-luc from C3−/− were evaluated by confocal microscopy. (C) Primary tumor volumes 21 days after LLC-luc implantation in WT or C3−/− mice are shown (WT n = 18; C3−/− n = 11). (D and E) Number of metastases to the secondary pulmonary space and liver were counted from ex vivo images that captured the luciferase activities of LLC-luc metastases (Pulmonary metastasis - WT n = 18; C3−/− n = 11 and Liver metastasis - WT n = 14; C3−/− n = 9). (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 21 days after tumor implantation in both treated groups and vehicle or control peptide group are shown (F, n = 5 and G, n = 5 each group). *p <0.05. Error bars represent mean ± SEM.
    Figure Legend Snippet: Age and gender-matched WT and C3−/− mice were injected with LLC-luc tumors, and primary tumors, organs, and whole blood were collected at the terminal sacrifice 21 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or LLC-luc tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+LLC-luc n = 21; naïve C3−/− n = 4; C3−/−+LLC-luc n = 4). Same data from naïve WT and C3−/− mice are used in this graph. (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in tumor specimens induced by LLC-luc from C3−/− were evaluated by confocal microscopy. (C) Primary tumor volumes 21 days after LLC-luc implantation in WT or C3−/− mice are shown (WT n = 18; C3−/− n = 11). (D and E) Number of metastases to the secondary pulmonary space and liver were counted from ex vivo images that captured the luciferase activities of LLC-luc metastases (Pulmonary metastasis - WT n = 18; C3−/− n = 11 and Liver metastasis - WT n = 14; C3−/− n = 9). (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 21 days after tumor implantation in both treated groups and vehicle or control peptide group are shown (F, n = 5 and G, n = 5 each group). *p <0.05. Error bars represent mean ± SEM.

    Techniques Used: Injection, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Confocal Microscopy, Ex Vivo, Luciferase, Tumor Implantation

    complement c4  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Hycult Biotech complement c4
    Complement C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complement c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    complement c4 - by Bioz Stars, 2024-04
    92/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Hycult Biotech anti mouse c4
    Anti Mouse C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti mouse c4 - by Bioz Stars, 2024-04
    92/100 stars
      Buy from Supplier

    92
    Hycult Biotech c4, mouse, mab 16d2
    C4, Mouse, Mab 16d2, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c4, mouse, mab 16d2/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    c4, mouse, mab 16d2 - by Bioz Stars, 2024-04
    92/100 stars
      Buy from Supplier

    92
    Hycult Biotech rat anti c4b
    (A) UMAP visualization and annotation of 5 sub-clusters within the oligodendrocyte lineage across all samples; 2,300 cells at 3mo and 1,480 cells at 7mo. (B) Stacked bar graph displaying cell percentage of each cluster identifies the appearance of reactive oligodendrocytes (red bar) in 7mo APP23xPS45 and APP23xPS45xIPD mice. (C) Volcano plot showing DEGs between APP23xPS45 versus WT mice in the oligodendrocyte cluster at 7mo. (D) Violin plot showing the expression of <t>C4b,</t> Serpina3n and B2m within reactive oligodendrocytes (Cl.5) across all genotypes at 7mo. (E) Representative images of RNAscope-ISH for Serpina3n and Sox10 probes (upper panel) and immunofluorescence for C4b and Olig2 co-staining (lower panel) in the cortex of APP23xPS45 and APP23xPS45xIPD mice at 7mo. (F) Quantification of percentage and expression (denoted by puncta/cell) of Serpina3n and C4b in oligodendrocytes based on RNAscope-ISH and immunofluorescence images; n represents number of images from 3 independent mice. (G) Same as D, expression in 3mo mice. Error bars represent SEM. Unpaired t-test; p=0.8327, p=0.5367, p=0.3246, p=0.2215. Scale bar= 20μm upper panel, 50μm lower panel.
    Rat Anti C4b, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti c4b/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti c4b - by Bioz Stars, 2024-04
    92/100 stars
      Buy from Supplier

    92
    Hycult Biotech complement c4
    Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and <t>C4</t> (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.
    Complement C4, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complement c4/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    complement c4 - by Bioz Stars, 2024-04
    92/100 stars
      Buy from Supplier

    Image Search Results


    (A) UMAP visualization and annotation of 5 sub-clusters within the oligodendrocyte lineage across all samples; 2,300 cells at 3mo and 1,480 cells at 7mo. (B) Stacked bar graph displaying cell percentage of each cluster identifies the appearance of reactive oligodendrocytes (red bar) in 7mo APP23xPS45 and APP23xPS45xIPD mice. (C) Volcano plot showing DEGs between APP23xPS45 versus WT mice in the oligodendrocyte cluster at 7mo. (D) Violin plot showing the expression of C4b, Serpina3n and B2m within reactive oligodendrocytes (Cl.5) across all genotypes at 7mo. (E) Representative images of RNAscope-ISH for Serpina3n and Sox10 probes (upper panel) and immunofluorescence for C4b and Olig2 co-staining (lower panel) in the cortex of APP23xPS45 and APP23xPS45xIPD mice at 7mo. (F) Quantification of percentage and expression (denoted by puncta/cell) of Serpina3n and C4b in oligodendrocytes based on RNAscope-ISH and immunofluorescence images; n represents number of images from 3 independent mice. (G) Same as D, expression in 3mo mice. Error bars represent SEM. Unpaired t-test; p=0.8327, p=0.5367, p=0.3246, p=0.2215. Scale bar= 20μm upper panel, 50μm lower panel.

    Journal: bioRxiv

    Article Title: Sustained TREM2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer’s disease

    doi: 10.1101/2021.06.23.449405

    Figure Lengend Snippet: (A) UMAP visualization and annotation of 5 sub-clusters within the oligodendrocyte lineage across all samples; 2,300 cells at 3mo and 1,480 cells at 7mo. (B) Stacked bar graph displaying cell percentage of each cluster identifies the appearance of reactive oligodendrocytes (red bar) in 7mo APP23xPS45 and APP23xPS45xIPD mice. (C) Volcano plot showing DEGs between APP23xPS45 versus WT mice in the oligodendrocyte cluster at 7mo. (D) Violin plot showing the expression of C4b, Serpina3n and B2m within reactive oligodendrocytes (Cl.5) across all genotypes at 7mo. (E) Representative images of RNAscope-ISH for Serpina3n and Sox10 probes (upper panel) and immunofluorescence for C4b and Olig2 co-staining (lower panel) in the cortex of APP23xPS45 and APP23xPS45xIPD mice at 7mo. (F) Quantification of percentage and expression (denoted by puncta/cell) of Serpina3n and C4b in oligodendrocytes based on RNAscope-ISH and immunofluorescence images; n represents number of images from 3 independent mice. (G) Same as D, expression in 3mo mice. Error bars represent SEM. Unpaired t-test; p=0.8327, p=0.5367, p=0.3246, p=0.2215. Scale bar= 20μm upper panel, 50μm lower panel.

    Article Snippet: List of primary antibodies used: Rabbit anti-amyloid fibrils OC (1:1000; Merck AB2286), Rabbit anti-Iba1 (1:1000; Wako, 019-19741), Sheep anti-Trem2 (1:500; R&D systems, AF1729), Rat anti-CD68 (1:500; Biorad, MCA1957), Goat anti-Olig2 (1:300; R&D systems, AF2418), Rat anti-C4b (1:100; Hycult, HM1046), Mouse anti-APP (1:100; Sigma, MAB348).

    Techniques: Expressing, Immunofluorescence, Staining

    Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.

    Journal: Cancer research

    Article Title: Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression

    doi: 10.1158/0008-5472.CAN-17-0240

    Figure Lengend Snippet: Age matched WT and C3−/− mice were injected with CMT-luc tumors, and the primary tumors, organs, and whole blood were collected at the terminal sacrifice 28 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+CMT-luc n = 5; naïve C3−/− n = 4; C3−/−+CMT-luc n = 9). (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in the primary tumor specimens from WT mice were evaluated by confocal microscopy. (C) Primary tumor volumes 10 or 28 days after CMT-luc implantation in WT or C3−/− mice are shown. (Day 10: WT n = 6 and C3−/− n = 6; Day 28: WT n = 10 and C3−/− n = 9) (D) Number of metastases to the secondary pulmonary space were counted from ex vivo images that captured the luciferase activities of CMT-luc metastases. (WT n = 11; C3−/− n = 9) (E) Flank tumor volumes 28 days after CMT-luc implantation in WT or C3−/− are shown (WT n = 31; Day 28 C3−/− n = 12) (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 28 days after tumor implantation in the treated groups and vehicle or control peptide group are shown (F, n = 4 and G, n = 10 each group). *p <0.05. Error bars represent mean ± SEM.

    Article Snippet: Primary antibodies specific for complement C3 (FITC goat IgG to mouse complement C3, MP Biomedicals, #55500, 1:200 dilution), IgM (Cy3 goat anti-mouse IgM, µ-chain specific, Jackson ImmunoResearch, #115-165-020, 1:400 dilution), and complement C4 (Anti-mouse C4, clone 16D2, Hycult, #HM1046, 1:50 dilution) were diluted in sterile-filtered 2% heat-inactivated goat serum in DPBS and incubated overnight.

    Techniques: Injection, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Confocal Microscopy, Ex Vivo, Luciferase, Tumor Implantation

    Age and gender-matched WT and C3−/− mice were injected with LLC-luc tumors, and primary tumors, organs, and whole blood were collected at the terminal sacrifice 21 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or LLC-luc tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+LLC-luc n = 21; naïve C3−/− n = 4; C3−/−+LLC-luc n = 4). Same data from naïve WT and C3−/− mice are used in this graph. (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in tumor specimens induced by LLC-luc from C3−/− were evaluated by confocal microscopy. (C) Primary tumor volumes 21 days after LLC-luc implantation in WT or C3−/− mice are shown (WT n = 18; C3−/− n = 11). (D and E) Number of metastases to the secondary pulmonary space and liver were counted from ex vivo images that captured the luciferase activities of LLC-luc metastases (Pulmonary metastasis - WT n = 18; C3−/− n = 11 and Liver metastasis - WT n = 14; C3−/− n = 9). (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 21 days after tumor implantation in both treated groups and vehicle or control peptide group are shown (F, n = 5 and G, n = 5 each group). *p <0.05. Error bars represent mean ± SEM.

    Journal: Cancer research

    Article Title: Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression

    doi: 10.1158/0008-5472.CAN-17-0240

    Figure Lengend Snippet: Age and gender-matched WT and C3−/− mice were injected with LLC-luc tumors, and primary tumors, organs, and whole blood were collected at the terminal sacrifice 21 days post-injection. (A) ELISA specific for murine C3a was used to measure C3a in the plasma samples collected from naïve or LLC-luc tumor-bearing WT and C3−/− mice (Naïve WT n = 3; WT+LLC-luc n = 21; naïve C3−/− n = 4; C3−/−+LLC-luc n = 4). Same data from naïve WT and C3−/− mice are used in this graph. (B) Immunofluorescence co-staining for C3 (green) and IgM (red) or C3 (green) and C4 (red) in tumor specimens induced by LLC-luc from C3−/− were evaluated by confocal microscopy. (C) Primary tumor volumes 21 days after LLC-luc implantation in WT or C3−/− mice are shown (WT n = 18; C3−/− n = 11). (D and E) Number of metastases to the secondary pulmonary space and liver were counted from ex vivo images that captured the luciferase activities of LLC-luc metastases (Pulmonary metastasis - WT n = 18; C3−/− n = 11 and Liver metastasis - WT n = 14; C3−/− n = 9). (F-G) WT mice are administered with (F) C3a receptor antagonist (C3aRA; SB290157) or (G) PMX-53 (C5a receptor antagonist, C5aRA), starting a day prior to tumor implantation into WT mice. Primary tumor volumes 21 days after tumor implantation in both treated groups and vehicle or control peptide group are shown (F, n = 5 and G, n = 5 each group). *p <0.05. Error bars represent mean ± SEM.

    Article Snippet: Primary antibodies specific for complement C3 (FITC goat IgG to mouse complement C3, MP Biomedicals, #55500, 1:200 dilution), IgM (Cy3 goat anti-mouse IgM, µ-chain specific, Jackson ImmunoResearch, #115-165-020, 1:400 dilution), and complement C4 (Anti-mouse C4, clone 16D2, Hycult, #HM1046, 1:50 dilution) were diluted in sterile-filtered 2% heat-inactivated goat serum in DPBS and incubated overnight.

    Techniques: Injection, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Confocal Microscopy, Ex Vivo, Luciferase, Tumor Implantation